We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.
- Authors
Detweiler^Short, K.; Rajkumar, S. V.; Larson, D.; Buadi, F.; Hayman, S.; Dispenzieri, A.; Gertz, M.; Kumar, S.; Mikhael, J.; Roy, V.; Kyle, R. A.; Lacy, M. Q.; Short, K Detweiler
- Abstract
We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years following diagnosis of MM was 3%. The response of EMD to pomalidomide plus low-dose dexamethasone included two complete and two partial responses among the 13 patients (response rate, 31%). Overall survival measured from trial entry was significantly shorter for patients with treatment-emergent EMD compared with those who did not have EMD, (median 16 months versus not reached, P=0.002).
- Subjects
MULTIPLE myeloma treatment; MULTIPLE myeloma diagnosis; TREATMENT effectiveness; DISEASE incidence; MAYO Clinic; DEXAMETHASONE; CLINICAL trials; CLINICAL medicine; ANTINEOPLASTIC agents; COMPARATIVE studies; RESEARCH methodology; MEDICAL cooperation; MULTIPLE myeloma; RESEARCH; RESEARCH funding; SURVIVAL; EVALUATION research; THALIDOMIDE; PHARMACODYNAMICS; THERAPEUTICS
- Publication
Leukemia (08876924), 2011, Vol 25, Issue 6, p906
- ISSN
0887-6924
- Publication type
journal article
- DOI
10.1038/leu.2011.29